Anaplastic thyroid cancer: Genome-based search for new targeted therapy options
DA Hescheler, MJM Hartmann… - Endocrine …, 2022 - ec.bioscientifica.com
Objective Anaplastic thyroid cancer (ATC) is one of the most lethal human cancers with
meager treatment options. We aimed to identify the targeted drugs already approved by the …
meager treatment options. We aimed to identify the targeted drugs already approved by the …
Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: A case report
Y Zhang, X Deng, Z Ding, J Kang, B Wu, B Guo, Y Fan - Medicine, 2021 - journals.lww.com
Interventions: Apatinib (500 mg orally once a day) was initially used to treat this patient as a
neoadjuvant therapy. Outcomes: Six weeks later, the tumor dramatically shrunk from 56× 37 …
neoadjuvant therapy. Outcomes: Six weeks later, the tumor dramatically shrunk from 56× 37 …
Advances in targeted therapy for anaplastic thyroid carcinoma.
C Qian, L Jiang, S Xu, J Wang, Z Tan… - … da xue xue bao. Yi xue …, 2021 - europepmc.org
甲状腺未分化癌 (ATC) 是一种恶性程度高, 侵袭性强的甲状腺恶性肿瘤, 发病迅速, 预后差,
目前尚缺乏有效治疗手段. 分子靶向治疗为 ATC 治疗提供了一种新思路. 酪氨酸激酶抑制剂乐伐 …
目前尚缺乏有效治疗手段. 分子靶向治疗为 ATC 治疗提供了一种新思路. 酪氨酸激酶抑制剂乐伐 …
Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
W Jia, Z Liu, L Zhan, Q Zhao, W Qiu… - Journal of Clinical …, 2022 - mdpi.com
Thyroid cancer (TC) is the most prevalent endocrine malignancy, with a rising incidence in
the past decade. Based on the derivation of neoplasms, TC comprises thyroid follicular …
the past decade. Based on the derivation of neoplasms, TC comprises thyroid follicular …
[HTML][HTML] 甲状腺未分化癌靶向治疗研究进展
Q Chenhong, L JIANG, XU Shiying… - Journal of Zhejiang …, 2021 - ncbi.nlm.nih.gov
甲状腺未分化癌（ ATC） 是一种恶性程度高、 侵袭性强的甲状腺恶性肿瘤， 发病迅速， 预后差，
目前尚缺乏有效治疗手段。 分子靶向治疗为ATC 治疗提供了一种新思路 …
目前尚缺乏有效治疗手段。 分子靶向治疗为ATC 治疗提供了一种新思路 …
[PDF][PDF] 阿帕替尼致手足综合征临床及文献病例分析
韩梅， 葛明， 刘月娥 - 药物不良反应杂志, 2020 - cadrj.com
目的探讨阿帕替尼相关手足综合征(HFS) 的临床特点. 方法检索PubMed, 维普,
中国知网和万方数据库(截至2019 年3 月20 日), 收集阿帕替尼相关HFS 文献病例报告 …
中国知网和万方数据库(截至2019 年3 月20 日), 收集阿帕替尼相关HFS 文献病例报告 …
[PDF][PDF] Progress in study on apatinib in treatment of both radioactive iodine refractory and more aggressive thyroid carcinoma
Z Ling, QIU Weihua - Journal of Surgery Concepts & Practice, 2021 - qk.sjtu.edu.cn
甲状腺癌是内分泌系统常见的恶性肿瘤, 以分化型甲状腺癌常见. 虽然手术切除, 131I
治疗及促甲状腺素抑制等标准治疗预后较好, 但仍可发生肿瘤局部复发, 颈淋巴结或远处转移 …
治疗及促甲状腺素抑制等标准治疗预后较好, 但仍可发生肿瘤局部复发, 颈淋巴结或远处转移 …
[引用][C] Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
W Jia, Z Liu, L Zhan, Q Zhao, W Qiu, J Kuang - Journal of clinical … - europepmc.org
Thyroid cancer (TC) is the most prevalent endocrine malignancy, with a rising incidence in
the past decade. Based on the derivation of neoplasms, TC comprises thyroid follicular …
the past decade. Based on the derivation of neoplasms, TC comprises thyroid follicular …